Trial Profile
A Phase 1b Dose Escalation Study Evaluating the Safety and Pharmacokinetics of Venetoclax in Combination With Azacitidine in Subjects With Treatment-Naive Higher-Risk Myelodysplastic Syndromes (MDS)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 30 Jan 2024
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Venetoclax (Primary)
- Indications Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors AbbVie
- 12 Dec 2023 Results ( data cutoff of May 31, 2023, n=107 ) assessing Efficacy and Safety of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Myelodysplastic Syndromes presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results ( At the data cutoff of May 31, 2023, n=124 )clinical outcomes of patients with HR-MDS who proceeded to SCT following combination Ven+Aza treatment, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 25 Jan 2023 Planned End Date changed from 9 Jul 2023 to 28 Jun 2024.